丹诺医药成立于2013年，是一家以临床需求为导向，专门从事差异化抗菌新药产品研发的生物制药公司。拥有一个独特的多靶点偶联分子抗菌新药研发平台和一个全球知识产权保护的抗菌新药产品研发管线，目标适应症包括医疗器械相关生物膜感染、肝硬化肝性脑病和幽门螺杆菌感染等适应症，以解决这些领域未满足临床需求，为中国乃至全球患者提供安全有效的治疗手段。
Location: China, Gansu, Suzhou
Employees: 11-50
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | 6 Dimensio... | 6dimension... |
| - | Northern L... | nlvc.com |
Mentions in press and media 7
| Date | Title | Description |
| 20.10.2024 | TenNor Raises Over RMB300M Financing | TenNor Therapeutics, a Suzhou, China-based clinical stage company dedicated to developing new therapies for infectious diseases, raised over RMB300M in Series E funding. Backers included AMR Action Fund, Zhongshan Venture Capital and other ... |
| 18.10.2024 | The Race Against Resistance: TenNor and SONIRE's Innovations in Healthcare | In the world of medicine, innovation is the lifeblood that keeps hope alive. Two companies, TenNor Therapeutics and SONIRE Therapeutics, are at the forefront of this race. They are tackling some of the most pressing health challenges today:... |
| 16.10.2024 | TenNor Announces More than 300 Million RMB Financing to Support Development and Commercialization of Late-Stage Assets Including Rifasutenizol for Heliobacter pylori Infections | SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the initial closing of a Series E financing roun... |
| 22.11.2021 | TenNor Reports Positive Results of TNP-2092 Capsule for the Treatment of Liver Cirrhosis Hyperammonemia | SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- TenNor Therapeutics reports positive top-line results for TNP-2092 Capsule from a phase II clinical trial for the treatment of hyperammonemia/hepatic encephalopathy in patients with liver cirrhos... |
| 19.09.2016 | TenNor Therapeutics Raises $25M Series B Financing | TenNor Therapeutics, a Suzhou, China-based clinical stage company focused on the development of dual-acting antibiotics, raised $25m in Series B financing. The round was led by Northern Light Venture Capital with participation from current ... |
| - | TenNor Therapeutics | “Danyo Pharmaceutical was established in 2013, is a biological pharmaceutical company specializing in the research and development of different antimicrobial new drugs.There is a unique multi-point combination of molecular antimicrobial New... |
| - | TenNor Therapeutics | “Tanbo-i-yoku” |